Medicinova Stock Price, News & Analysis

MediciNova, Inc. (NASDAQ: MNOV) has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent concerning MN-001 (tipelukast) and its metabolite MN-002, which target hepatic ballooning. This patent is anticipated to be granted by January 2035 and covers various oral administration forms. The Chief Medical Officer highlighted MN-001's efficacy in improving NASH pathology in animal models. MediciNova is focused on developing therapies for inflammatory and fibrotic diseases, currently advancing multiple clinical programs, including MN-166 for ALS.

MediciNova, a biopharmaceutical company trading as MNOV, announced receiving a Notice of Intention to Grant from the European Patent Office for MN-166 (ibudilast), targeting alcohol use disorder (AUD). This patent, expected to expire no earlier than May 2037, covers various dosage regimens and combination therapies. Clinical trials have shown MN-166 significantly reduces heavy drinking and alcohol cravings. The company aims to meet the high unmet medical need for AUD treatments, with ongoing studies funded by the NIH and collaborations with UCLA.

MediciNova, Inc. announced receiving a Notice of Intention to Grant from the European Patent Office for MN-001 (tipelukast) and MN-002 related to inhibiting hepatic ballooning, with expected patent expiration in January 2035. The claims cover oral forms and various dosages. MN-001 has shown promising results in improving NASH pathology in animal models, with significant NAFLD activity score improvements. The company is focused on developing therapies for fibrotic and neurodegenerative diseases, with MN-166 also in late-stage trials for ALS and MS.

MediciNova, traded as MNOV on NASDAQ, announced a Notice of Allowance from the U.S. Patent Office for a patent covering the combination of MN-166 (ibudilast) and riluzole for treating amyotrophic lateral sclerosis (ALS). This patent is expected to expire no earlier than November 2035 and includes various dosage forms. Chief Medical Officer Kazuko Matsuda stated that this patent will enhance the company's ALS patent portfolio. ALS affects approximately 16,000 patients in the U.S. annually, highlighting the potential market for MN-166.

MediciNova, Inc. (NASDAQ: MNOV) announced the presentation of its ongoing Phase 2b/3 clinical trial of MN-166 (ibudilast) for amyotrophic lateral sclerosis (ALS) at the 32nd International Symposium on ALS/MND, held virtually from December 7-10, 2021. Dr. Malath Makhay detailed the trial's objectives, design, and recent adaptations to enhance patient participation. The trial aims to enroll 230 patients across 30 sites, with the primary endpoint being the change in ALSFRS-R score at 12 months. CEO Dr. Yuichi Iwaki highlighted the trial's importance and the addition of new recruitment sites.

MediciNova (NASDAQ:MNOV) has announced promising results from a study presented by Dr. Justin Lathia at the Society for Neuro-Oncology's annual meeting regarding the efficacy of MN-166 (ibudilast) in combination with PD-1 inhibitors for treating glioblastoma (GBM). The study demonstrated a median survival increase from 28 days with PD-1 alone to 66 days when combined with MN-166, a significant finding (p<0.001). MediciNova aims to progress to clinical trials based on these encouraging outcomes, underscoring the potential of MN-166 to enhance GBM treatment.

MediciNova, Inc. (NASDAQ:MNOV) announced a study by Dr. Masatsune Ogura, revealing MN-001 (tipelukast) reduces triglyceride (TG) synthesis in liver cells. Presented at The Liver Meeting 2021, findings indicate that MN-001 inhibits TG synthesis by suppressing CD36 expression, a fatty acid transporter, in HepG2 cells. Compared to untreated cells, TG synthesis increased significantly with arachidonic acid and LXR agonist T0901317. MN-001 shows potential in addressing nonalcoholic steatohepatitis (NASH) by improving lipid metabolism.

MediciNova, Inc. (NASDAQ:MNOV) announced promising findings regarding MN-166 (ibudilast) in a uveal melanoma model presented by Dr. Grazia Ambrosini at the 10th Annual CURE OM Global Science Meeting. The study indicated that MN-166 significantly reduced migration of UM cells and prevented metastasis in mice. Key mechanisms involve macrophage migration inhibitory factor (MIF). This data positions MN-166 as a potential preventive treatment for uveal melanoma, addressing critical unmet needs in this area. The company aims to proceed to clinical trials to evaluate MN-166's efficacy in combating cancer metastasis.

MediciNova, Inc. (NASDAQ:MNOV) announced that Dr. Justin Lathia from the Cleveland Clinic will present new findings on MN-166 (ibudilast) in a glioblastoma animal model at the 26th Annual Meeting of the Society for Neuro-Oncology in Boston, scheduled for November 18-21, 2021. The presentation will occur on November 20, focusing on the role of myeloid cells in glioblastoma. MN-166 is a compound in late-stage clinical development for various neurodegenerative diseases and conditions, showcasing its potential in a range of therapeutic areas.